Caught in the middle:MARCH5 mediates PD-1-induced IL-2R degradation  

作　　者：Xinghao Wang Weiping Zou 

机构地区：[1]Department of Surgery,University of Michigan Medical School,Ann Arbor,MI,USA [2]Center of Excellence for Cancer Immunology and Immunotherapy,University of Michigan Rogel Cancer Center,University of Michigan Rogel Cancer Center,Ann Arbor,MI,USA [3]Graduate Program in Immunology,University of Michigan,Ann Arbor,MI,USA [4]Graduate Program in Cancer Biology,University of Michigan,Ann Arbor,MI,USA [5]University of Michigan Rogel Cancer Center,University of Michigan,Ann Arbor,MI,USA [6]Department of Pathology,University of Michigan Medical School,Ann Arbor,MI,USA

出　　处：《Cell Research》2024年第1期3-4,共2页细胞研究（英文版）

摘　　要：Blockade of the PD-L1/PD-1 pathway in combination of IL-2 therapy appears to yield synergistic anti-tumor immunity in the treatment of various cancers.In a recent paper published in Cell Research,Liu et al.uncover previously unknown synergistic mechanisms and identify FDA-approved pitavastatin as a potential drug to facilitate such synergy.

关 键 词：IMMUNITY SYNERGISTIC 

分 类 号：Q2[生物学—细胞生物学]